Published in Ann Neurol on September 01, 2008
Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat (2009) 1.69
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.37
Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A (2013) 1.24
Toxoplasma secreting Cre recombinase for analysis of host-parasite interactions. Nat Methods (2010) 1.20
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome (2011) 1.17
Candidate drug targets for prevention or modification of epilepsy. Annu Rev Pharmacol Toxicol (2014) 1.15
Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci (2013) 1.14
Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A (2010) 1.13
Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci (2013) 1.11
NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci (2012) 1.08
Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A (2012) 1.06
EP2 receptor signaling pathways regulate classical activation of microglia. J Biol Chem (2013) 1.02
Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics (2010) 1.02
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem (2010) 0.97
Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal (2014) 0.96
Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2. Am J Pathol (2009) 0.94
Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm (Vienna) (2010) 0.93
Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radic Biol Med (2011) 0.92
A plural role for lipids in motor neuron diseases: energy, signaling and structure. Front Cell Neurosci (2014) 0.91
Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm (2012) 0.91
Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity. Neurotoxicology (2011) 0.91
Prostaglandin signalling in cerebral ischaemia. Br J Pharmacol (2010) 0.89
Lead optimization studies of cinnamic amide EP2 antagonists. J Med Chem (2014) 0.88
Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery. ASN Neuro (2015) 0.87
Prostanoid receptor EP2 as a therapeutic target. J Med Chem (2013) 0.86
Eryptosis as a marker of Parkinson's disease. Aging (Albany NY) (2014) 0.86
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. Hum Mol Genet (2014) 0.84
Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis (2015) 0.84
Development of second generation EP2 antagonists with high selectivity. Eur J Med Chem (2014) 0.83
The importance of molecular histology to study glial influence on neurodegenerative disorders. Focus on recent developed single cell laser microdissection. J Mol Histol (2009) 0.82
Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus. Neuropharmacology (2015) 0.82
The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice. Endocrinology (2015) 0.81
Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Exp Mol Pathol (2013) 0.80
Prostaglandin E2 reverses aberrant production of an inflammatory chemokine by microglia from Sandhoff disease model mice through the cAMP-PKA pathway. PLoS One (2011) 0.79
Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms. Mol Brain (2013) 0.79
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease. Curr Immunol Rev (2015) 0.78
Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation. Clin Lipidol (2011) 0.77
EP2 Receptor Signaling Regulates Microglia Death. Mol Pharmacol (2015) 0.77
Cerebroprotection by the neuronal PGE2 receptor EP2 after intracerebral hemorrhage in middle-aged mice. J Cereb Blood Flow Metab (2016) 0.77
Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide. J Neuroinflammation (2017) 0.75
Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling. Mol Pharmacol (2017) 0.75
Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2. Expert Opin Ther Pat (2015) 0.75
Anti-Inflammatory and Neuroprotective Effects of PGE2 EP4 Signaling in Models of Parkinson's Disease. J Neuroimmune Pharmacol (2016) 0.75
Microglia control the glycinergic but not the GABAergic synapses via prostaglandin E2 in the spinal cord. J Cell Biol (2017) 0.75
Increased Expression of 15-Hydroxyprostaglandin Dehydrogenase in Spinal Astrocytes During Disease Progression in a Model of Amyotrophic Lateral Sclerosis. Cell Mol Neurobiol (2016) 0.75
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron (2006) 7.82
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol (2001) 4.40
Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 4.06
Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res (2001) 3.94
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron (2002) 3.31
Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science (2005) 3.05
Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci (1997) 2.55
Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol (2004) 2.45
SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest (2008) 2.42
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci (2004) 2.40
Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci U S A (2005) 2.30
Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve (2002) 2.25
Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05
Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J (2007) 1.93
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A (2006) 1.90
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol (2006) 1.87
Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging (2007) 1.62
Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol (2001) 1.55
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol (2002) 1.52
Redox modifier genes in amyotrophic lateral sclerosis in mice. J Clin Invest (2007) 1.46
PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res (1986) 1.44
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol (2004) 1.27
Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol (1998) 1.18
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem (2004) 1.17
On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal (2006) 1.17
Divergent effects of prostaglandin receptor signaling on neuronal survival. Neurosci Lett (2007) 1.14
Distribution, regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur J Neurosci (1999) 1.12
Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol (1999) 1.12
A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (2003) 1.10
Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology (2002) 1.02
Function of COX-2 and prostaglandins in neurological disease. J Mol Neurosci (2007) 1.02
Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology (2001) 1.00
Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci (2003) 0.95
Targeted gene disruption of the prostaglandin E2 EP2 receptor. Adv Exp Med Biol (2002) 0.81
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Ballistic carbon nanotube field-effect transistors. Nature (2003) 4.35
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther (2004) 3.40
Fluorescence visualization of newly synthesized proteins in mammalian cells. Angew Chem Int Ed Engl (2006) 2.96
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Severe fever with thrombocytopenia syndrome virus, Shandong Province, China. Emerg Infect Dis (2012) 2.77
Polarization-controlled tunable directional coupling of surface plasmon polaritons. Science (2013) 2.73
Improvement of Fat Graft Survival with Autologous Bone Marrow Aspirate and Bone Marrow Concentrate: A One-Step Method. Plast Reconstr Surg (2016) 2.59
A fluorogenic 1,3-dipolar cycloaddition reaction of 3-azidocoumarins and acetylenes. Org Lett (2004) 2.57
Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation (2006) 2.50
Cilium-generated signaling and cilia-related disorders. Lab Invest (2005) 2.42
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci (2004) 2.40
Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med (2012) 2.38
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol (2003) 2.22
GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data. Bioinformatics (2012) 2.21
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
High-kappa dielectrics for advanced carbon-nanotube transistors and logic gates. Nat Mater (2002) 2.18
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Modeling elastic properties in finite-element analysis: how much precision is needed to produce an accurate model? Anat Rec A Discov Mol Cell Evol Biol (2005) 2.01
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99
An investigation of the mechanisms of electronic sensing of protein adsorption on carbon nanotube devices. J Am Chem Soc (2004) 1.98
Effect of oral ALA supplementation on oxidative stress and insulin sensitivity among overweight/obese adults: a double-blinded, randomized, controlled, cross-over intervention trial. Int J Cardiol (2012) 1.98
OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY. Retina (2016) 1.93
Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell (2007) 1.90
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res (2010) 1.89
Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c. Dev Cell (2007) 1.88
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Electron transport in very clean, as-grown suspended carbon nanotubes. Nat Mater (2005) 1.86
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med (2005) 1.85
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Selective dye-labeling of newly synthesized proteins in bacterial cells. J Am Chem Soc (2005) 1.77
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Cilia and flagella revealed: from flagellar assembly in Chlamydomonas to human obesity disorders. Cell (2004) 1.76
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol (2009) 1.76
ABSORB: Atlas Building by Self-organized Registration and Bundling. Neuroimage (2010) 1.75
An aurora kinase is essential for flagellar disassembly in Chlamydomonas. Dev Cell (2004) 1.75
Thermal conductance of an individual single-wall carbon nanotube above room temperature. Nano Lett (2006) 1.73
LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.72
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 1.72
Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol (2009) 1.71
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res (2009) 1.70
High-field quasiballistic transport in short carbon nanotubes. Phys Rev Lett (2004) 1.68
The feeding biomechanics and dietary ecology of Australopithecus africanus. Proc Natl Acad Sci U S A (2009) 1.66
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Self-directed self-assembly of nanoparticle/copolymer mixtures. Nature (2005) 1.62
Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res (2013) 1.61
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest (2002) 1.56
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol (2011) 1.54
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
A novel Crumbs3 isoform regulates cell division and ciliogenesis via importin beta interactions. J Cell Biol (2007) 1.53
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol (2008) 1.52
Hydrogen-rich saline reduces the oxidative stress and relieves the severity of trauma-induced acute pancreatitis in rats. J Trauma Acute Care Surg (2012) 1.50
Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis (2006) 1.49
The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem (2010) 1.48
An experimental design to study adipocyte stem cells for reconstruction of calvarial defects. J Craniofac Surg (2009) 1.47
Genome-scale transcriptome analysis of the desert poplar, Populus euphratica. Tree Physiol (2011) 1.47
Prioritizing risk pathways: a novel association approach to searching for disease pathways fusing SNPs and pathways. Bioinformatics (2008) 1.46
A cone-beam computed tomography study of maxillary first permanent molar root and canal morphology in a Chinese population. J Endod (2010) 1.45
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest (2007) 1.45
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
Surface modification of tobacco mosaic virus with "click" chemistry. Chembiochem (2008) 1.43
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42
Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res (2009) 1.42
Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules (2003) 1.42
Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J Am Coll Cardiol (2004) 1.41